BPA Call 36C26123A0025-36C26125N0101
Award Date
10/1/24
Potential Completion Date
9/30/25
Potential Value
$743K
Federal Agency
Veterans Integrated Service Network 21
Awardee
Progenics Pharmaceuticals Inc.
Ultimate Awardee
Lantheus Holdings, Inc.
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
North Billerica, Billerica, MA 01862, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Department of Veterans Affairs (VA) awarded a $3,424,675.28 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. This contract is not set aside and is part of a larger Blanket Purchase Agreement (BPA) valued at $5.5 million, which the VA...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract, valued at $328,671.99, has an ultimate completion date of July 4, 2023. Progenics Pharmaceuticals primarily provides...
The Department of Veterans Affairs (VA) awarded a $538,099.28 firm-fixed-price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the radiopharmaceutical product PYLARIFY (piflufolastat F-18). PYLARIFY is a diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. The contract is not set aside and is part of a larger Blanket Purchase Agreement (BPA) valued at $5.5 million, which facilitates the...
The U.S. Department of Veterans Affairs (VA) awarded a firm fixed price delivery order contract worth $886,927.68 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract has an ultimate completion date of January 14, 2024 and is not set aside for any specific business...
The U.S. Department of Veterans Affairs (VA) awarded a $3,320,022.40 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. This contract, which has an ultimate completion date of September 22, 2029, is not set aside and is associated with...
The U.S. Department of Veterans Affairs (VA) and the Defense Health Agency (DHA) have awarded a $793,918.40 firm-fixed-price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the radiopharmaceutical product PYLARIFY (piflufolastat F-18). This diagnostic agent is used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The contract, which is not set aside, has an ultimate completion date of August...
The U.S. Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used for prostate cancer positron emission tomography (PET) imaging. The contract, valued at $765,048.64, has a period of performance through February 29, 2024. PYLARIFY is the flagship product of Progenics Pharmaceuticals, a pharmaceutical company...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) to Progenics Pharmaceuticals Inc., a subsidiary of Lantheus Holdings, Inc., for the supply of PYLARIFY (piflufolastat F-18), a radioactive diagnostic agent used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The BPA, with a ceiling value of $1,400,749.44, is part of the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) contract and will allow various VA...
The U.S. Department of Veterans Affairs (VA) awarded a $925,328.45 firm fixed price delivery order contract to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. The contract is for the delivery of PYLARIFY, a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) scans to detect and image prostate cancer. This delivery order is part of a larger Blanket Purchase Agreement (BPA) with the VA, valued at $5.5 million, which facilitates the ongoing...
The U.S. Department of Veterans Affairs (VA) awarded a 1-year, firm fixed-price delivery order worth $1,030,850.32 to Progenics Pharmaceuticals Inc., a division of Lantheus Medical Imaging, Inc. This contract is for the provision of PYLARIFY (piflufolastat F-18), a radiopharmaceutical used in positron emission tomography (PET) scans to detect, localize, and image prostate cancer. The award was not set aside for any specific business type. Progenics Pharmaceuticals is a subsidiary of the parent...